MedTrace Logo

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS

NCT03462498 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3008

Last updated 2024-06-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES) under the setting of acute coronary syndrome (ACS).

Conditions

  • Acute Coronary Syndrome
  • Acute Myocardial Infarction
  • Coronary Artery Disease
  • Percutaneous Coronary Intervention
  • Platelet Aggregation Inhibitors

Interventions

DRUG

1-months DAPT

1-month DAPT followed by 59-month monotherapy

DRUG

12-month DAPT

12-month DAPT followed by 48-month monotherapy

Sponsors & Collaborators

  • Kyoto University, Graduate School of Medicine

    lead OTHER

Principal Investigators

  • Takeshi Kimura, MD · Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-02
Primary Completion
2021-12-31
Completion
2026-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03462498 on ClinicalTrials.gov